<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821353</url>
  </required_header>
  <id_info>
    <org_study_id>N N402 194635</org_study_id>
    <secondary_id>1.7/IV/08</secondary_id>
    <nct_id>NCT00821353</nct_id>
  </id_info>
  <brief_title>Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy</brief_title>
  <official_title>Sinus Rhythm Maintenance in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation - Randomized Comparison of Antiarrhythmic Therapy vs. Radiofrequency Catheter Ablation (SHAARC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cardiology, Warsaw, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Cardiology, Warsaw, Poland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paroxysmal or chronic atrial fibrillation (AF) develops in about 20- 25% of adult patients
      with hypertrophic cardiomyopathy (HCM) and represents an important complication in the
      clinical course of the disease, with adverse long-term consequences on functional status and
      outcome.

      Therefore, aggressive therapeutic strategies are indicated to restore and maintain sinus
      rhythm (SR) in patients with HCM. Nevertheless, pharmacologic prevention of AF recurrence is
      challenging because of the limited long-term efficacy and potentially hazardous side effects
      of available treatment options. Currently radiofrequency catheter ablation (RFCA) of AF is
      successfully used in clinical practice. However, comparison of the efficacy and safety of
      these two therapeutic options has not been done up till now in randomized manner in this
      group of patients.

      Thus, the aim of the present study is to compare the efficacy and safety of RFCA vs.
      antiarrhythmic drug therapy in patients with HCM and AF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Freedom from atrial fibrillation and atrial flutter (&gt;1 min) on or off antiarrhythmic medications.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in total symptomatic and asymptomatic AF burden.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in left atrial diameter and left ventricular function.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in level of Nt-pro-BNP.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in symptom severity and quality of life.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in exercise capacity assessed by cardiopulmonary exercise testing.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>RFCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RF catheter ablation</intervention_name>
    <description>RF catheter ablation</description>
    <arm_group_label>RFCA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiarrhythmic drugs</intervention_name>
    <description>One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hypertrophic cardiomyopathy and paroxysmal or chronic atrial
             fibrillation

        Exclusion Criteria:

          -  Severe hear failure (NYHA IV)

          -  Left ventricular ejection fraction &lt;0.30

          -  Left atrial diameter &gt;65 mm

          -  Age &gt; 70 years

          -  Contraindication to anticoagulation with warfarin

          -  Presence of a mechanical prosthetic valve

          -  Presence of left atrial thrombus on TEE or CT

          -  Woman currently pregnant

          -  Renal failure (GFR &lt; 30 ml/min)

          -  Hepatic failure

          -  Untreated hypothyroidism or hyperthyroidism

          -  LVOT gradient &gt; 50 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pawel Derejko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Cardiology, Warsaw, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lidia Chojnowska, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Cardiology, Warsaw, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lukasz Szumowski, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Cardiology, Warsaw, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franciszek Walczak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Cardiology, Warsaw, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2009</study_first_submitted>
  <study_first_submitted_qc>January 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2009</study_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2013</last_update_posted>
  <responsible_party>
    <name_title>Pawel Derejko M.D. Ph.D.</name_title>
    <organization>Institute of Cardiology, Warsaw, Poland</organization>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Hypertrophic cardiomyopathy</keyword>
  <keyword>RF ablation</keyword>
  <keyword>Antiarrhythmic drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

